Drugmaker Dr. Reddy’s Laboratories has released Febuxostat Tablets, a therapeutic equal generic model of Uloric (Febuxostat) Tablets, in the U.S. market.
A release from Dr. Reddy’s, citing IQVIA Wellness figures, claimed the Uloric brand name and generic experienced U.S. gross sales of all-around $108 million MAT for the 12 months finished Oct 2020. The products is for the management of hyperuricemia or substantial uric acid amount in grownup sufferers with gout. Uloric is a trademark of Japanese agency Teijin.
The launch by Dr. Reddy’s follows approval from the U.S. Food stuff and Drug Administration (USFDA) and the Febuxostat Tablets are offered in 40 mg and 80 mg strengths in bottle count dimensions of 30 tablets, the launch stated.